Serrapeptase for Exercise Recovery

Verdict: Weak, contested; no exercise-recovery evidence

Serrapeptase has no controlled trials for exercise recovery or muscle soreness, and the post-surgical data it borrows from is inconsistent and low-quality. The evidence does not support taking it to speed athletic recovery.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The grade is weak (Tier C) because every trial actually measures post-dental-surgery recovery, not exercise recovery, and the results conflict. A 2018 meta-analysis (PMID 29618875) and a 2021 industry-funded RCT (PMID 33653320, n=133) found serrapeptase improved jaw mobility (trismus) after impacted-molar extraction, but pain was no better than placebo. A 2023 GRADE-rated meta-analysis went further, finding serrapeptase reduces trismus but does NOT reduce swelling, inflammation, or pain.

Where serrapeptase has been compared head-to-head, it lost: in a 2013 RCT (PMID 23649050) dexamethasone controlled swelling and pain better. Trial quality is rated low throughout (small, old, biased), and crucially, no controlled trial of serrapeptase for muscle soreness or athletic recovery exists at all — so its popularity as a recovery supplement rests on extrapolation, not data.

Regulators reinforce the doubt. The FDA bars disease-treatment claims; the EU and UK classify serrapeptase as an unauthorised novel food and make it illegal to sell as a supplement. Japan withdrew the prescription version (Danzen/Dasen) in 2011 after post-marketing double-blind trials failed to beat placebo. Mayo, Cleveland Clinic, and Harvard take no position. Established recovery strategies — adequate sleep and managed training load — have far stronger support.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.47
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
71%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.472
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Role of Serratiopeptidase After Surgical Removal of Impacted Molar: A Systematic Review and Meta-analysis
PMID: 29618875 2018 統合分析 n = 5
Finding: Serratiopeptidase improved trismus better than corticosteroids on days 1/3/5/7 (MD 4.42, 95% CI 3.84 to 5.00); corticosteroids reduced swelling better than serratiopeptidase on day 1 (MD 2.95, 95% CI 0.83 to 5.07) with no significant difference thereafter; pain meta-analysis could not be completed due to heterogeneous reporting. Authors concluded serratiopeptidase could be used safely and effectively for trismus and swelling.
🟠 Limited quality Effect size: Trismus MD 4.42 mm vs corticosteroids; swelling favored corticosteroids day 1 only (MD 2.95)
View on PubMed
Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial
PMID: 33653320 2021 RCT (double-blind) n = 133
Finding: Treatment group showed significantly better trismus by day 4 (27.30 ± 7.3 mm vs 32.06 ± 7.7 mm, P<0.001) and less swelling (earlobe-to-symphysis 111.49 ± 8.1 mm vs 115.39 ± 9.9 mm, P<0.001); pain showed no statistically significant difference between groups.
⚠️ Industry-funded Effect size: Trismus and swelling significant favoring serratiopeptidase; pain NS
View on PubMed
Comparison of the roles of serratiopeptidase and dexamethasone in the control of inflammation and trismus following impacted third molar surgery
PMID: 23649050 2013 隨機對照試驗 n = 110
Finding: Dexamethasone was more effective than serratiopeptidase for reducing swelling and pain; both agents had equivalent effect on trismus.
🟠 Limited quality Effect size: Dexamethasone superior for swelling/pain; equivalent for trismus
View on PubMed
Efficacy of serratiopeptidase in third molar surgery. A systematic review and meta-analysis
PMID: 2023 統合分析 n = 6
— See PubMed for details
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Products may be legally marketed as dietary supplements if claims about diagnosis, cure, mitigation, treatment, or prevention are removed from promotional materials and the products otherwise comply with all applicable provisions of the Act and FDA regulations. source↗
L4b EU EFSA
Against
L4c UK NHS
Against
Serratiopeptidase is an unauthorised novel food, and it is illegal for businesses to sell serrapeptase as a food supplement for human consumption in the EU and UK because it is an unauthorised novel food. source↗
L4d TW TFDA / 衛福部
Neutral
適應症:手術後及外傷後之消炎、副鼻腔炎、膀胱炎、副睪丸炎、智齒周圍炎、齒槽膿瘍之消炎、支氣管炎。 source↗
L5a NIH Office of Dietary Supplements
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-recovery-INT-serrapeptase-001 繁體中文版 →